Cat.No. | Name | Information |
---|---|---|
M45137 | Fuzapladib | Fuzapladib is a leukocyte adhesion molecule and an orally active inhibitor of leukocyte function-associated antigen type 1 (LFA-1) activation.Fuzapladib is also a phospholipase A2 (PLA2) inhibitor, which exerts anti-inflammatory activity by inhibiting the migration of leukocytes to sites of inflammation. |
M45136 | PF-07220060 | PF-07220060 is a potent CDK4/CDK6 inhibitor with Ki values of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3. |
M45135 | Dalpiciclib hydrochloride | Dalpiciclib hydrochloride is an orally active and highly selective CDK4/6 inhibitor with IC50 values of 12.4 nM and 9.9 nM, respectively.Dalpiciclib hydrochloride showed antitumor activity against breast cancer and esophageal squamous cell carcinoma. |
M45133 | Eplontersen | Eplontersen is an N-acetylgalactosamine (GalNAc3)-suffixed antisense oligonucleotide (ASO) that targets the mRNA of the thyroxine transporter protein, TTR, and inhibits both variant and wild-type TTR production. It can be used in studies related to amyloidotic polyneuropathy. |
M45132 | Palopegteriparatide | Palopegteriparatide is a long-acting precursor compound of parathyroid hormone (PTH), as well as a calcium-sensitive receptor (CaSR) antagonist, and a parathyroid hormone receptor (PTH1R) modulator, and may be used in studies related to hypoparathyroidism (HP). |
M45131 | Ongericimab | Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody. |
M45130 | NNC0385-0434 | NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies. |
M45129 | CiVi-008 | CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism. |
M45128 | CiVi-007 | CiVi-007 is an antisense oligonucleotide (ASO) polymerized with N-acetylglucosamine that targets PCSK9 and can be used in studies related to hypercholesterolemia. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.